Document Detail


Premarket clinical evaluation of novel cardiovascular devices: quality analysis of premarket clinical studies submitted to the Food and Drug Administration 2000-2007.
MedLine Citation:
PMID:  20038828     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The quality of clinical data submitted by manufacturers to support Food and Drug Administration cardiovascular device premarket approval (PMA) applications varies widely and formal quality assessment has not been previously performed. This study evaluated all original cardiovascular device PMAs with Food and Drug Administration decisions between January 1, 2000, and December 31, 2007, to assess the quality of clinical investigations submitted by manufacturers. Effectiveness and safety end points were judged high quality if they were clearly defined and associated with a specific time point for analysis. Subject accounting was high quality if 90% or greater of the original cohort was accounted for at study conclusion. In total, 88 cardiovascular device PMAs (77.3% permanent implants), 132 clinical studies, 37,328 study subjects (age 61.0 +/- 14.5 years, 33.9% women, 86.3% white), and 29,408 device recipients were analyzed. All PMAs contained clinical data. Primary effectiveness end points, primary safety end points, and subject accounting were deemed high quality in 81.8%, 60.2%, and 77.3% of pivotal studies, respectively. Key cardiovascular comorbidities (coronary artery disease 51.1%, diabetes 36.6%, hypertension 35.2%, heart failure 37.5%, tobacco use 31.8%) and race (14.8%) were infrequently reported, and studies rarely included patients younger than 18 years of age (10.2% of studies). Poorly defined safety and effectiveness end points, poor patient accounting, and incomplete collection of important patient comorbidities make device safety and effectiveness assessments more challenging. Women, pediatric, and nonwhite populations are underrepresented in premarket cardiovascular clinical trials. Manufacturers, regulators, and the clinical community should collaborate to address these study shortcomings to ensure that patients are treated with reliable, safe, and clinically useful medical devices.
Authors:
Daniel B Kramer; Elias Mallis; Bram D Zuckerman; Barbara A Zimmerman; William H Maisel
Related Documents :
16522028 - Self-assembled boron nanowire y-junctions.
10100388 - The fda and regulatory issues in graft development.
10150658 - Rabbit fallopian tube reanastomosis using a microvascular stapling device.
11028238 - From symbols to flesh: the polymorphous destiny of narration.
11141258 - Analytical procedure for quantifying five compounds suspected as possible contaminants ...
18053228 - Aspects of statin prescribing in norwegian counties with high, average and low statin c...
Publication Detail:
Type:  Journal Article; Research Support, U.S. Gov't, Non-P.H.S.    
Journal Detail:
Title:  American journal of therapeutics     Volume:  17     ISSN:  1536-3686     ISO Abbreviation:  Am J Ther     Publication Date:    2010 Jan-Feb
Date Detail:
Created Date:  2010-01-22     Completed Date:  2010-03-03     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9441347     Medline TA:  Am J Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2-7     Citation Subset:  IM    
Affiliation:
Cardiovascular Institute, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Age Factors
Aged
Bias (Epidemiology)
Cardiovascular Diseases / therapy*
Clinical Trials as Topic / methods,  standards*
Device Approval*
Endpoint Determination
Equipment Safety
Equipment and Supplies
Female
Humans
Male
Middle Aged
Patient Selection
United States
United States Food and Drug Administration
Young Adult

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Blood pressure treatment in acute ischemic stroke: a review of studies and recommendations.
Next Document:  Enhanced anticancer effect of gemcitabine by genistein in osteosarcoma: the role of Akt and nuclear ...